Looking for more Scientific Resources

The William Guy Forbeck Research Foundation is working with the scientific community to shortening the cancer research timetable.

Charlie’s Paddle for Cancer Research

February 9, 2015

My name is Charlie Howden and I have had a dream of paddling the west coast of Costa Rica to raise money for a charity.   Who knew that I would be doing it while battling Pancreatic Cancer. I am from Eastbourne, East Sussex in the South East of England and have always been keen in

Scholars Dr. Sarosiek and Dr. Wood Collaborate on Research

The Forbeck Foundation is proud to announce that two, 2012 Forbeck Scholars Dr. Kris Sarosiek and Dr. Kris Wood published a collaborative research paper! The Forbeck Foundation brings together top scientists and researchers to collaborate and shorten the cancer research timetable. We are excited when Scholars and Researchers work together after meeting at a Forbeck meeting. Titled:

Annual Forum 2015 – Immunotherapy

January 13, 2015

Dr.Catherine Bollard, Washington Children’s Hospital, Washington, DC Dr. Daniel Powell, University of Pennsylvania, Philadelphia, PA   Immunotherapy  Some of the most exciting results in cancer medicine, in the last decade, have come about by treating relapsed patients with B cell lymphoma with their own T cells that have been modified to attack the tumor cells.

University of Chicago to Establish a Comprehensive Computational Facility

December 29, 2014

The Forbeck Foundation is a top supporter of the INRGdb, housed at the University of Chicago. “The Genomic Data Commons has the potential to transform the study of cancer at all scales,” said Robert Grossman, director of the Genomic Data Commons project and professor of  medicine at University of Chicago.  “It supplies the data so

2014 Newsletter – Resistance Mechanisms

November 19, 2014

CHAIRMEN Joan Brugge, Ph.D. Harvard Medical School Boston, MA Jeffrey Engelman MD, Ph.D. Massachusetts General Hospital Boston, MA OVERVIEW Cancer therapies that specifically target the genetic alterations associated with subsets of advanced cancers have shown impressive success in the clinic.  Examples include ABL inhibitors fro chronic myelogenous leukemia, RAF inhibitors for BRAF mutant melanomas, EGFR